Phibro Animal Health Corporation

PAHC Healthcare Drug Manufacturers Specialty & Generic

Phibro Animal Health Corporation’s revenue for fiscal 2026 (year ended June 2026) was $1.5 billion, up 17.1% from fiscal 2025. In the quarter to June 2026, revenue grew 4.77%, EPS grew 28.6%, free cash flow fell 35.7% and total debt rose 1.96%, each against the same quarter a year earlier. Dividend growth for ten consecutive years, revenue growth for five; insiders bought in the last twelve months.

38.82 0.84 +2.21%
Market cap
$1.5B
P/E
15.8×
Fwd P/E
11.1×
Dividend yield
1.24%
F-score
6/9
Altman Z
2.95
Beneish M
−2.39
Dividend safety
47/100

A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.

Jun '26 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21 Jun '20 Jun '19 Jun '18 Jun '17
Net Income
99.72 48.26 2.42 32.61 49.18 54.39 33.55 54.71 64.88 64.62
Operating Cash Flow
68.95 80.12 87.59 13.31 31.65 48.31 59.35 47.17 70.01 98.39
Investing cash flow
(71.45) (288.69) (48.19) (74.02) (22.58) (18.58) (120.39) (14.13) (84.61) (21.94)
Financing cash flow
(6.56) 207.13 (6.77) 26.99 16.34 (16.99) 40.94 (4.11) (11.77) (53.74)
Ending Cash
61.42 68.04 70.61 41.28 74.25 50.21 36.34 57.57 29.17 56.08
Other line items

Show all line items

In millions of $ except per-share values · columns are period end dates